1 / 36

STEMI PREPARAZIONE ALLA ANGIOPLASTICA NEGLI OSPEDALI SENZA EMODINAMICA

PAF 2010. La preparazione alla PTCA nelle SCA PREPARAZIONE FARMACOLOGICA ALLA PTCA: DALLE LINEE GUIDA AI DATI DEGLI STUDI E DEI REGISTRI. STEMI PREPARAZIONE ALLA ANGIOPLASTICA NEGLI OSPEDALI SENZA EMODINAMICA. Francesco Chiarella Ospedale S.Corona Pietra Ligure. CENSIMENTO 2005.

tobias-gregory
Télécharger la présentation

STEMI PREPARAZIONE ALLA ANGIOPLASTICA NEGLI OSPEDALI SENZA EMODINAMICA

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. PAF 2010 La preparazione alla PTCA nelle SCA PREPARAZIONE FARMACOLOGICA ALLA PTCA:DALLE LINEE GUIDA AI DATI DEGLI STUDI E DEI REGISTRI STEMIPREPARAZIONE ALLA ANGIOPLASTICANEGLI OSPEDALISENZA EMODINAMICA Francesco Chiarella Ospedale S.Corona Pietra Ligure

  2. CENSIMENTO 2005 1 UTIC / 136.500 ab. 1 letto UTIC / 21.816 ab. 5° Censimento Federativo Strutture Cardiologiche

  3. BLITZ-3: provenienza ricoveri UTIC DA SPOKE AD HUB SOLO 15% ! HUB 177

  4. PREPARAZIONE FARMACOLOGICA A PTCA OSPEDALI SENZA EMODINAMICA:DALLE LINEE GUIDA AI DATI DEGLI STUDI E DEI REGISTRI Linee Guida: rielaborazioni annuali su STEMI e PCI da Comitati Congiunti di 5 Società Scientifiche

  5. IIa IIa IIa IIa IIb IIb IIb IIb III III III III I I I IIa IIa IIa IIa IIb IIb IIb IIb III III III III I I I IIa IIa IIa IIa IIb IIb IIb IIb III III III III I I I C UPDATE 2009 IMPRESCINDIBILITA’ DI PROTOCOLLI CONDIVISI • Ogni comunità deve sviluppare un protocollo (“sistema di cure”) per lo STEMI • Team multidisciplinare • Sistema Emergenza Territoriale • Ospedale/i no Cath-Lab (“Spoke”) • Ospedale/i con Cath Lab (“Hub”) ACC/AHA 2009 Joint STEMI/PCI Guidelines Focused Update

  6. QUALE FARMACO? ACC/AHA 2009 Joint STEMI/PCI Guidelines Focused Update A ciascun Pz il suo percorso A ciascun Pz il suo trattamento

  7. Pathway: Triage and Transfer for PCI (in STEMI) STEMI patient who is a candidate for reperfusion Initially seen at a non-PCI capable facility Initially seen at a PCI capable facility Initial Treatment with fibrinolytic therapy (Class 1, LOE:A) Send to Cath Lab for primary PCI (Class I, LOE:A) Transfer for primary PCI (Class I, LOE:A) Tempo da angor < 3 h Tempo al pallone > 1 h Basso score rischio / no rischio emorr. Tempo da angor > 3 h Tempo al pallone < 1 h Alto score di rischio / rischio emorragico HIGH RISK Transfer to a PCI facility is reasonable for early diagnostic angio & possible PCI or CABG (Class IIa, LOE:B), High-risk patients as defined by 2007 STEMI Focused Update should undergo cath (Class 1: LOE B) NOT HIGH RISK Transfer to a PCI facility may be considered (Class IIb, LOE:C), especially if ischemic symptoms persist and failure to reperfuse is suspected Prep antithrombotic (anticoagulant plus antiplatelet) regimen Diagnostic angio Medical therapy only PCI CABG 2009 STEMI Focused Update. Appendix 5

  8. IIa IIa IIa IIa IIb IIb IIb IIb III III III III I I I IIa IIa IIa IIa IIb IIb IIb IIb III III III III I I I IIa IIa IIa IIa IIb IIb IIb IIb III III III III I I I C Update 2009 A tutti prima possibile: La dose di carico di tienopididine è raccomandata per tutti STEMI Clopidogrel almeno 300 – 600 mg appena possibile a tutti i pazienti avviati a PCI primaria o non primaria. Studi di dose finding hanno dimostrato che aumentando il dosaggio si inibiscono PTL più rapidamente, 300600900, ma la sicurezza e l’efficacia clinica non sono ancora rigorosamente stabilite, ACC/AHA 2009 Joint STEMI/PCI Guidelines Focused Update 8

  9. IIa IIa IIa IIa IIb IIb IIb IIb III III III III I I I IIa IIa IIa IIa IIb IIb IIb IIb III III III III I I I IIa IIa IIa IIa IIb IIb IIb IIb III III III III I I I B MODIFIED Recommendation STEMI: PREPARAZIONE ALLA ANGIOPLASTICANEGLI OSPEDALISENZA EMODINAMICA entra PRASUGREL STEMI  PCI primaria Prasugrel 60 mg should be given as soon as possible for primary PCI. Limitazioni: età > 75 storia di TIA o stroke, “active bleeding” urgente BPAC anticoagulanti peso < 60 Kg

  10. TRITON-TIMI 38 Wiviott SD et al AHJ 152: 627,2006 Adapted with permission from E.Antman ACS (STEMI or UA/NSTEMI) & Planned PCI N= 13,600 ASA Double-blind CLOPIDOGREL 300 mg LD/ 75 mg MD PRASUGREL 60 mg LD/ 10 mg MD Median duration of therapy - 12 months 1o endpoint: CV death, MI, Stroke 2o endpoints: CV death, MI, Stroke, Rehosp-Rec Isch CV death, MI, UTVR Stent Thrombosis (ARC definite/prob.) Safety endpoints: TIMI major bleeds, Life-threatening bleedsKey Substudies: Pharmacokinetic, Genomic 10

  11. Balance of Efficacy and Safety TRITON: Results 15 138 events The number of subjects who would need to be treated to result in one excess major bleed (NNH) was 167 Clopidogrel HR 0.81(0.73-0.90)P=0.0004 12.1 CV Death / MI / Stroke 9.9 10 NNT = 46 Endpoint (%) Prasugrel Trattare 46 x prevenire un evento 35 events 5 TIMI Major NonCABG Bleeds Prasugrel HR 1.32(1.03-1.68)P=0.03 2.4 1.8 Clopidogrel NNH = 167 0 0 30 60 90 180 270 360 450 Trattare 167 x causare un bleeding Days Adapted with permission from Wiviott SD et al NEJM 357:2007

  12. STEMI CohortN=3534 TRITON TIMI-38 15 CV Death / MI / Stroke Clopidogrel 12.4% 9.5% 10.0% 10 HR 0.79 Percent (%) (0.65-0.97) Prasugrel 6.5% P=0.02 NNT = 42 HR 0.68 (0.54-0.87) 5 P=0.002 TIMI Major NonCABG Bleeds 2.4 Prasugrel 2.1 Clopidogrel 0 0 30 60 90 180 270 360 450 Days From Randomization Montalescot et al Lancet 2008.Adapted with permission from Antman EM. 12

  13. beneficio nei primi 3 gg e nei 18 mesi Timing of Benefit(Landmark Analysis - 3 days) TRITON TIMI-38 8 6.9 Clopidogrel Clopidogrel 5.6 5.6 6 Primary Endpoint (%) 4.7 4 Prasugrel Prasugrel HR 0.82P=0.01 HR 0.80P=0.003 2 1 0 0 1 2 3 0 30 60 90 180 270 360 450 Loading Dose Maintenance Dose Days Adapted with permission from Antman EM JACC 2008. 13

  14. IIa IIa IIa IIa IIb IIb IIb IIb III III III III I I I IIa IIa IIa IIa IIb IIb IIb IIb III III III III I I I IIa IIa IIa IIa IIb IIb IIb IIb III III III III I I I B MODIFIED Rec For STEMI undergoingnon-primary PCIcarico prasugrel dopo coronarografia pre-PTCA ( entro 1 h) the following regimens are recommended: • If the patient did not receive fibrinolytic therapy… • …eithera loading dose of 300-600 mg of clopidogrel should be given or, • once the coronary anatomy is known and PCI is planned, a loading dose of 60 mg of prasugrel should be given promptly and no later than 1 hour after the PCI. ACC/AHA 2009 Joint STEMI/PCI Guidelines Focused Update 14

  15. Ticagrelor ! antagonist of recettore adenosinico P2Y12 PLATO: 18.624 STEMI e NSTEMI random ticagrelor vs clopidogrel (180-mg loading dose, 90 mg twice daily thereafter) (300-to-600-mg loading dose, 75 mg daily thereafter). NEJM, 361:1045-1057 2009

  16. PCI “facilitata” e “rescue”: termini obsoleti (molto attuali) I termini “facilitated PCI” e “rescue PCI” non dovrebbero più essere usati “ Contemporary therapeutic choices leading to reperfusion for pts with STEMI can be described without these potentially misleading labels” confondenti rispetto a obiettivo riperfusione Cambio concettuale: la riperfusione è l’obiettivo, non si parlerà più di “facilitazione” e di “rescue”, termini giudicati confondenti e obsoleti che siamo invitati a mandare in cantina ACC/AHA 2009 Joint STEMI/PCI Guidelines Focused Update

  17. CARESS Transfer-AMI FINESSE STEMI alto rischio • Combined Abciximab REteplase Stent Study in AMI per testare fibrinolisi+PCI subito vs fibrinolisi + PCI rescue > • Trial of Routine ANgioplasty and Stenting after Fibrinolysis • to Enhance Reperfusion in nAMI (TRANSFER-AMI) per testare ½ fibrinolisi + ABCX + PCI >

  18. CARESS-IN-AMI:DISEGNATO ALLA RICERCA DEL MIGLIORE TRATTAMENTO PER I PZ CON STEMI NEGLI OSPEDALI NO CATH-LAB 600 STEMI <75 years old > 1 high risk feature RETEPLASE ½ dose, ABCX, heparin, ASA Randomizzazaione a trasferimento immediato x pci o trasferimento x rescue o differito “Not a trial of facilitated angioplasty opposed to primary angioplasty”

  19. CARESS-IN-AMI: Primary Outcome STEMI con immediata PCI: minor numero di eventi avversi a 30 gg Non differenze significative di sanguinamenti RETEPLASE ½ dose, ABCX, heparin, ASA 10.7% 4.4% immediata pci Di Mario et al. Lancet 2008;371. CARESS: legittima reteplase metà dose, ABCX, eparina, ASA e poi trasferire

  20. TRANSFER-AMIStudio di strategia farmacoinvasiva in 1059 STEMI alto rischiogiunti entro 12 ore da esordio ad ospedale senza cathlab A tutti: - TNK standard-dose, ASA, UFH or enoxaparin Clopidogrel loading 300mg for pts < 75 age 75 mg for pts >75 age Giunti nel Centro con CathLab: GP IIb/IIIa receptor antagonists according to institutions’ standard practice PCI RISULTERA’ DISEGNO: TNK STANDARD E PCI ENTRO 24 H VERSUS TTNK STANDARD E PCI DIFFERITA > 24 H 2.8 hrs 32 hrs 2b 3a solo negli osp con cathlab Cantor et al. N Eng J Med 2009;360:26.

  21. TRANSFER-AMI: CONCLUSIONI In STEMI ad alto rischio che si presentano a Ospedale Spoke: - fibrinolisi con TNK dose standard , clopidogrel - trasferimento a Hub per eseguire subito angiografia e PCI “without waiting to determine whether reperfusion has occurred” . via libera a PCI dopo TNK ! Cantor et al. N Eng J M 2009;360:26.

  22. Recommendations for the Use of Glycoprotein IIb/IIIa Receptor Antagonists in STEMI

  23. Use of Glycoprotein IIb/IIIa Receptor Antagonists in STEMI I I I I I I IIa IIa IIa IIa IIa IIa IIa IIa IIb IIb IIb IIb IIb IIb IIb IIb III III III III III III III III I I I I I I IIa IIa IIa IIa IIa IIa IIa IIa IIb IIb IIb IIb IIb IIb IIb IIb III III III III III III III III I I I I I I IIa IIa IIa IIa IIa IIa IIa IIa IIb IIb IIb IIb IIb IIb IIb IIb III III III III III III III III A B Modified Recommendation • E’ RAGIONEVOLE INIZIARE IL TRATTAMENTO CON ANTI IIb/IIIa AL MOMENTO DI ANGIOPLASTICA (CON O SENZA STENTING) • abciximab • tirofiban, eptifibatide IIb IIIa in sala

  24. I I I IIa IIa IIa IIa IIb IIb IIb IIb III III III III I I I IIa IIa IIa IIa IIb IIb IIb IIb III III III III I I I IIa IIa IIa IIa IIb IIb IIb IIb III III III III B Modified Recommendation Use of Glycoprotein IIb/IIIa Receptor Antagonists in STEMI la sentenza: pre Cath-Lab incerta utilità L’UTILITA’ DI ANTI IIb/IIIa COME STRATEGIA FARMACOLOGICA DI PREPARAZIONE ALLA ANGIOPLASTICA prior to arrival in the cardiac catheterization laboratory for angiography and PCI is uncertain.

  25. finesse = ABCX pre-PCI ½ -dose lytic + ABCX pre-PCI ABCX alone ABCX at time of PCI I risultati del FINESSE pubblicati dopo le Linee Guida riaccendono la disputa

  26. finesse = ABCX FINESSE: Study design Ellis et al. N Eng J Med. 2008;358:2205-2217.

  27. FINESSE a 1 anno N = 397 N = 2452 Considerando solo “alto rischio, tempo < 4 ore” STEMI alto rischio a centro spoke entro 4h 1/2 RETEPLASE + ABCX TORNA E VINCE Meno morti a 1 anno !

  28. Recommendations for Use of Parenteral Anticoagulants in Patients with STEMI

  29. Use of Parenteral Anticoagulants in STEMI IIa IIa IIa IIa IIa IIa IIa IIa IIb IIb IIb IIb IIb IIb IIb IIb III III III III III III III III I I I I I I IIa IIa IIa IIa IIa IIa IIa IIa IIb IIb IIb IIb IIb IIb IIb IIb III III III III III III III III I I I I I I IIa IIa IIa IIa IIa IIa IIa IIa IIb IIb IIb IIb IIb IIb IIb IIb III III III III III III III III I I I I I I B C Modified Recommendation IL TRATTAMENTO ANTICOAGULANTE RACCOMANDATO NEGLI STEMI PTCA PRIMARIAINCLUDE: • UN BOLO AGGIUNTIVO DI EPARINA NON FRAZIONATA • PER I PZ CHE GIA’ LA ASSUMEVANO per mantenere • un adeguato regime di scoagulazione (misurare ACT) • BIVALIRUDINA , CON O SENZA PRECEDENTE EPARINA entra bivalirudina ! Enoxaparin and fondaparinux unchanged from 2007 STEMI Focused Update

  30. HORIZONS-AMI: Design Emergency angiography Emergency angiography • Endpoints: Composite of net adverse clinical events (NACE) • Included major bleeding plus MACE (a composite of CVD death, reinfarction, target-vessel revascularization for ischemia, and stroke within 30 days) Stone et al. N Eng J Med. 2008;358:2218-30.

  31. HORIZONS-AMI: Time-to-Event Curves through 30 days: NetAdverse Clinical Events 3602 patients with STEMI & symptom onset ≤ 12 hours randomized 1802 HR=0.75, (0.62-0.92); p=0.006] 1800 Meno eventi avversi a 30 gg con bivalirudina da sola piuttosto che con eparina non frazionata + anti IIb/IIIa Stone et al. N Eng J Med. 2008;358:2218-30. QS STUDIO MOTIVA INDICAZIONE CLASSE I

  32. HORIZONS-AMI: Time-to-Event Curves through 30 days: Major Bleeding HR=0.59 (0.45-0.76) p<0.0001 bleeding - 40% a 30 gg Meno sanguinamenti a 30 gg con bivalirudina da sola piuttosto che con eparina non frazionata + anti IIb/IIIa Stone et al. N Eng J Med. 2008;358:2218-30.

  33. HORIZONS-AMI: Results (cont.) • Treatment with bivalirudin compared with UFH plus GP IIb/IIa inhibitors resulted in significantly lower: • 30-day death rates from cardiac causes (1.8% vs. 2.9%; RR 0.62; 95% CI 0.40 to 0.95; p=.03), & • 30-day death from all causes (2.1% vs. 3.1%; RR 0.66; 95% CI 0.44 to 1.00; p=0.047) • At one year, MACE rates were identical, but there was a decrease in all-cause mortality with bivalirudin (3.4% versus 4.8%, p=0.03). bivalirudina - morti a 30 gg - morti a 1 anno

  34. Use of Parenteral Anticoagulants in STEMI IIa IIa IIa IIa IIb IIb IIb IIb III III III III I I I IIa IIa IIa IIa IIb IIb IIb IIb III III III III I I I IIa IIa IIa IIa IIb IIb IIb IIb III III III III I I I B Modified Recommendation IL TRATTAMENTO ANTICOAGULANTE RACCOMANDATO NEGLI STEMI PTCA PRIMARIA INCLUDE: • BIVALIRUDINA Enoxaparin and fondaparinux unchanged from 2007 STEMI Focused Update

  35. Unfractionated heparin (UFH) administration guided by: Therapeutic activated clotting time (ACT) levels Prior administration of GP IIb/IIIa receptor antagonists Enoxaparin and fondaparinux unchanged from 2007 Enoxaparin, if the last subcutaneous dose was administered at least 8 to 12 hours earlier, an IV (intravenous) dose of 0.3 mg/kg of enoxaparin should be given; if the last subcutaneous dose was administered within the prior 8 hours, no additional enoxaparin should be given. (Level of Evidence: B) Fondaparinux, administer additional intravenous treatment with an anticoagulant possessing anti-IIa activity, taking into account whether GP IIb/IIIa receptor antagonists have been administered. (Level of Evidence: C)

  36. STEMI PREPARAZIONE ALLA ANGIOPLASTICA NEGLI OSPEDALI SENZA EMODINAMICA TRITRON TIMI 38 TRANSFER-AMI CARESS FINESSE HORIZONS AMI TIENOPIRIDINE (Clopid. 300, Pras 60) TNK + EPARINA + IIbIIIa in sala RETEPLASE ½ + ABCX RETEPLASE ½ + ABCX o solo ABCX o ABCX in cathLab BIVALIRUDINA

More Related